Search

Your search keyword '"Shyr, Yu"' showing total 397 results

Search Constraints

Start Over You searched for: Author "Shyr, Yu" Remove constraint Author: "Shyr, Yu" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
397 results on '"Shyr, Yu"'

Search Results

1. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

2. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

4. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

5. Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections

7. Association of Social Determinants of Health with Time to Diagnosis and Treatment Outcomes in Idiopathic Subglottic Stenosis.

8. The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19

9. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

13. COVID-19 vaccination and breakthrough infections in patients with cancer

14. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

16. Interoperability of phenome-wide multimorbidity patterns: a comparative study of two large-scale EHR systems

20. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

23. Telephone-Based Guideline-Directed Medical Therapy Optimization in Navajo Nation: The Hózhó Randomized Clinical Trial.

24. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

25. Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer

27. A Specialized Epithelial Cell Type Regulating Mucosal Immunity and Driving Human Crohn’s Disease

28. Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer

32. Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial

33. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

34. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

35. Supplementary Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

36. Data from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

37. Abstract 798: SeroNet Pooling Project of immunocompromised populations

38. Supplementary Table 1 from Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

39. Data from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

44. Supplementary Figures 1-12, Tables 5-8, Methods from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

47. Supplementary Tables 1 through 3 and Supplementary Figures 1 through 4 from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

48. Supplementary Tables 1-4 from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

50. Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Catalog

Books, media, physical & digital resources